Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezigdomide + enapotamab in relapsed/refractory multiple myeloma (China Ib/IIa)
CTR20254564Phase 2Active
- Sponsor
- Celgene Corporation
- Start
- Nov 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mezigdomide, enapotamab in multiple myeloma (MM), sponsored by Celgene Corporation. Started Nov 2025; status: active.
02
Drugs
mezigdomideenapotamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20254564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254564.